initi buy pt
kodiak lead drug bigger better last longer
compar anti-vegf agent
ophthalmolog compani leverag antibodi biopolym
conjug abc platform long durabl intravitr medicin
lead product anti-vegf shown safeti robust efficaci
durabl retreat month beyond across major
phenotyp variabl retin diseas wet dme/dr rvo
believ antibodi biopolym conjug platform fulli
appreci platform allow longer durabl intravitr treatment
ivt would allow improv complianc efficaci fewer visit
platform valid lead drug candid anti-
vegf antibodi similar antibodi compon eylea lucenti
bispecif uveiti
like risk reward pivot phase dazzl non-inferior studi
vs eylea wet base phase data wet
week show mean chang bcva compar
harrier studi show week time point boevu
showedd eylea harrier studi dazzl data
non-inferior eylea show durabl longer eylea dose
see confid read-through phase data rvo dme
dr read could result dcf
data updat weekend angiogenesi confer miami
could give investor confid dazzl data kodiak pursu
approv across indic bla rvo primari
endpoint data sbla file wet pivot phase
data endpoint data dme dr
simpl stori two way look valuat
conserv approach could backdrop price pressur
anti-vegf market could price premium current
agent rebat potenti biosimilar use patient
adequ treat eylea lucenti use later
line therapi could captur market share
brand anti-vegf sale aggress scenario assum
perceiv highli differenti longer interv dose favor
visual acuiti improv physician place ahead eylea
scenario could take share perceiv better
patient offer real world coverag durabl case
could see even upsid
compani well-capit cash balanc includ
recent equiti financ royalti agreement cap
tr target
futur royalti exchang close jan fund
baker bro advisor bba provid cash runway beyond
catalyst phase data updat wet feb addit phase data updat
dme rvo dr pivot phase dazzl studi studi vs eylea treatment-
nave wet phase rvo data potenti approval/launch
valuat risk pt deriv probabl adjust dcf discount rate
appropri risk associ smid-cap biotech appli probabl
account phase success risk includ regulatori risk obtain approv
clinic risk provid sustain respons inferior eylea commerci risk
penetr anti-vegf market
page
buy sometim bigger better last longer
page
pm summari initi coverag buy pt
page
model pt use dcf discount rate termin valu
appli discount rate line smid cap termin growth rate
figur million
page
less base work present valu growth termin compani report strh kodiak scienc inc
pm summari initi buy pt
ophthalmolog compani leverag antibodi biopolym conjug abc platform long
durabl intravitr medicin lead product anti-vegf shown safeti robust efficaci
durabl retreat month beyond across major phenotyp variabl retin diseas wet
dme/dr rvo
believ antibodi biopolym conjug platform fulli appreci platform allow
longer durabl intravitr treatment ivt would allow improv complianc efficaci fewer
visit platform valid lead drug candid anti-vegf antibodi similar
antibodi compon eylea lucenti bispecif uveiti
like risk reward pivot phase dazzl non-inferior studi vs eylea wet
base phase data wet week show mean chang bcva compar
harrier studi show week time point beovu show eylea harrier
studi dazzl data non-inferior eylea show durabl longer eylea dose see
confid read-through phase data rvo dme dr read could result
dcf data updat weekend angiogenesi confer miami could give
investor confid dazzl data kodiak pursu approv across indic bla
rvo primari endpoint data sbla file wet pivot phase data
endpoint data dme dr
simpl stori two way look valuat view conserv approach
could backdrop price pressur anti-vegf market could price
premium current agent rebat potenti biosimilar use patient adequ treat
eylea lucenti use later line therapi could captur market
share brand anti-vegf sale aggress scenario assum perceiv highli
differenti longer interv dose favor visual acuiti improv physician place ksi-
ahead eylea scenario could take share perceiv better patient
offer real world coverag durabl case could see even upsid
page
pm summari initi buy pt
compani well-capit cash balanc includ recent equiti financ
royalti agreement cap futur royalti exchang close jan fund
baker bro advisor bba provid cash runway beyond
phase data updat wet feb addit phase data updat dme rvo dr
pivot phase dazzl studi studi vs eylea treatment-nav wet phase
rvo data potenti approval/launch
valuat risk pt deriv probabl adjust dcf discount rate appropri
risk associ smid-cap biotech appli probabl account phase success
risk includ regulatori risk obtain approv clinic risk provid sustain
respons inferior eylea commerci risk penetr intravitr anti-vegf market
page
like risk reward phase dazzl data could see addl upsid
base phase data like safety/efficaci profil durabl data
potenti differenti current anti-vegf
global brand anti-vegf sale regeneron hold eylea sale
roch rog swx nr lucenti sale thu current level
trade impli sale repres brand ivt anti-vegf market
ww sale
page
antibodi biopolym conjug platform allow durabl potenc ocular tissu
platform design maintain potent
effect drug level ocular tissu
platform allow durabl potenc
avail biocompat patent
believ capac
leverag platform build pipelin
see platform valid two asset
one undisclos pipelin product
anti-vegf backbon
shown safety/efficaci patient
retin vascular diseas
biolog activ dose level test
one triplet bispecif antibodi conjug
small-molecul drug
page
anti-vegf like lucenti conjug phosphorylcholin biopolym
antibodi biopolym conjug stabl linkag one antibodi one branch optic clear
behav like biolog ivt travers vitreou retina/choroid
aqueou exit system similar predic anti-vegf biolog fast system clearanc
phosphorylcholine-bas biopolym natur biocompat
phosphorylcholin primari lipid head group extern surfac human cell
demonstr lt safety/effect increas biocompat reduc nonspecif protein absorpt reduc
cell adhes coat surfac medic devic
page
gener anti-vegf bigger better last longer
design longer interv dose better durabl maintain safeti efficaci
high molecular weight formul strength may provid dose advantag
size extend durabl larger lucenti eylea respect
flattest ocular durabl curv suggest increas concentr advantag
time
favor safeti profil io inflamm ocular sae date drug-
relat mild/consist profil ivt
page
differenti safeti efficaci durabl profil could mean fewer inject
highli differenti anti-vegf molecul
ultrahigh molecular weight vs lucenti eylea increas intraocular durabl
phosphorylcholine-bas antibodi biopolym conjug increas ocular tissu bioavail preserv
bioactiv along increas stabil
increas formul strength deliv higher molar dose anti-vegf vs lucenti vs eylea
see sever biosimilar lucenti eylea develop view differenti
molecul better durabl compar current agent
improv durabl fewer dose may keep patient mechan longer prevent repeat
treatment overextens treatment interv
dose could allow requir frequenc inject fewer keep patient
diseas quiescent frequenc visit patient/physician suggest achiev
physician treat wamd anti-vegf look improv dose intervals/conveni superior
outcom durabl improv efficaci safeti
due dilig note physician patient seek two key aspect anti-vegf agent
fewer dose improv dose intervals/conveni superior outcom durabl
better outcom improv efficacy/safeti
see peak unadjust ww sale across wet dme rvo dr
page
phase data shown potent anti-vegf effect bcva improv retin dri
highlight earli phase data wet shown clinic benefit in-lin current
anti-vegf treatment mean chang baselin bcva week also see impress
retin dri durabl load phase
page
phase data across wamd dme rvo demonstr durabl
view differenti profil advantag current treatment address
improv durabl could enabl improv real world efficaci conveni patient stay
drug longer improv qol reduc patient drop rate
reduc patient burden fewer load mainten injections/visit
page
expand pipelin address high-preval ophthalm diseas
regulatori approv follow end-of-phas meet fda requir complet two
pivot studi rvo shorter endpoint one studi wamd data mid-
dme dr support potenti us approv across indic
could see initi data bispecif bioconjug
seek leverag platform expand pipelin includ triplet inhibitor
multifactori retin diseas dri neurodegen aspect glaucoma
page
see multipl catalyst next month fda file indic
phase dazzl studi top-lin data expect
could obtain regulatori approv launch rvo sbla file addit
indic wet dme potenti diabet retinopathi without dme well
advanc clinic
page
product candid descriptionindicationdevelop phaseupcom milestonestimingdazzl endpoint top-lin data pivot top-lin brvo endpoint crvo endpoint file earli approv top-lin data phase top-lin data file late inhibitor vegf trap taf protein biconjug target vascular leakag abnorm angiogenesi concurr inflamm present dmedmeind submisison vegf could provid synergist action toward reduc inflamm swell uveiti potenti improv vision prevent sight-threaten complicationsuveitisphas data dme uveit macular edema strh research compani amdphas built antivodi biopolym conjug platform design maintain potent effect drug level ocular tissu retin vascular diseasesdmedrphas
also see ivt anti-vegf product come play next year
highlight competitor regulatori decis phase data across retin diseas
may compet near-term howev believ safeti efficaci durabl
profil first-in-class
page
companyproductdescriptiontherapeut pegolvegf-target design ankyrin repeat protein darpin wamdbla decis eu expect bispecificwamd/dmephas yosemite/rhin dme data late phase tenaya/lucern wamd data late file data dme/rvo
across retin diseas unmet need durabl drug
accord kod parti market research retin specialist rs cite follow unmet need
improv durabl extend dose interv prn anti-vegf dose conveni
improv real world outcom physician want offer better vision outcom
reduc patient burden physician patient want therapi requir less frequent inject
anti-vegf load mainten promot complianc prevent discontinu
unmet need extend anti-vegf dose reduc treatment
page
average age onsetpreval overviewwet caus blind elderlydiabet macular edema frequent caus blind middl age adultsretin vein occlus common caus vision loss due vascular diseasediabet retinopathi w/o caus vision loss among diabet classifi npdr vs pdr kodiak scienc inc
anti-vegf market opportun across indic
world-wide eylea lucenti sale respect across retin
comparison second full year launch eylea reach wamd alon
lucenti reach first full year launch
page
approv datelucenti indicationapr retinopathyjan choroid neovascular mcnv feb dmeaug vein occlus rvo jun dateeylea indicationmay retinopathi dr aug dose schedul dmejul macular edema follow rvonov kodiak scienc inc
give probabl ksi see fv studi fail fv could go cash
assum credit model peak adjust sale ww assum peak
penetr wamd penetr rvo peak penetr dme
figur million
page
assum peak penetr across wamd rvo dme
us market build conserv assum price similar eylea/lucenti
appli blend averag inject per patient per year price ex-u
assum discount appli similar penetr rate across indic
page
us popul rate wet wet defici diagnosi treatment patient popul continu treat share treat rate rvo defici diagnosi treatment patient without patient popul continu treat share treat rate dme defici diagnosi treatment patient without patient popul continu treat share treat patient treat gross price increas sale
pivot dazzl durabl data hold could see addit indic upsid
pivot phase dazzl studi dose everi week
base phase data biopolym platform higher convict phase
dazzl data
page
dme rvo dr first approv like rvo sbla approv
indic shortli highlight next pipelin product develop dme
design platform deliv via intravitr ivt inject
demonstr abil fast potent clinic respons
platform differenti abil ocular durabl rapid system clearanc
improv bioavail biocompat stabil compar current treatment
larg size biopolym conjug allow slower ocular clearanc improv
ocular pk extend interv dose
lead product anti-vegf shown efficaci durabl phase pivot
phase wet data phase studi plan rvo dme dr
credit current level view see potenti upsid
earli give credit assign valu model
preliminari phase data could provid upsid stock
page
highli differenti improv efficaci durabl vs current anti-vegf
antibodi intermedi consist anti-vegf antibodi pharmacolog similar
lucenti inhibit vegf-medi neovascular vascular permeabl
biopolym compon branch optic clear phosphorylcholin biopolym
phosphorylcholin demonstr physiolog inert attribut molecular structur
perman posit charg group equal balanc neg charg phosphat
yield net neutral charg wide rang condit super hydrophil properti bind larg
amount water molecul tightli creat structur water
characterist
ultrahigh molecular weight improv key ocular pk ocular concentr advantag
platform increas ocular tissu bioavail vs eylea increas bioactiv
increas stability/resist degrad bioconjug
increas formul strength vs eylea lucenti measur weight
protein moieti higher number anti-vegf bind site per dose vs eylea lucenti respect
page
bispecif dme/uv diseas high ocular inflamm
bioconjug dual inhibitor taf trap-antibody-fus protein phosphorylcholine-
base biopolym ind submiss expect phase data
overview antibodi biopolym conjug
protein portion vegf bind domain vegf receptor act trap
solubl receptor decoy bind abund isoform vegf
anti-vegf trap domain fuse high-affin antibodi bind high specif
affin disrupt ligand associ cognat receptor
fc domain engin reduc immun effector function facilit site-
specif conjug biopolym
ultra-high molecular weight dalton improv ocular pk use
framework sequenc phosphorylcholine-bas biopolym
benefit enhanc tissu access ocular tissu stabil
page
dme/uv treatment paradigm address underli inflamm
anti-inflammatori treatment steroid effect treat uveiti
character spectrum diseas intraocular inflamm dme
shown simultan bind vegf inhibit downstream angiogen signal
pathway novel dual-inhibitor offer altern treatment option retin vascular
diseas especi high inflammatori compon and/or respond adequ
anti-vegf treatment alon
preclin data shown synergist abrog endotheli cell prolifer driven
concurr inflammatori vegf mediat signal shown inhibit vegf
mediat angiogen function test human vascular endotheli cell huvec prolifer assay
shown significantli reduc maxim growth neither eylea control
alon quantifi effect
page
platform offer safeti durabl differenti profil compar agent
product develop also seek extend durabl sustain releas implant
lucenti implant port deliveri system pd microparticl sunitinib tki
gene therapi also highlight anti-vegf agent
believ anti-vegf safe efficaci offer durabl data compar current
agent product novel drug develop
page
differenti phase durabl look encourag across wamd dme rvo
data cutoff wamd shown extend month
longer last load dose without receiv retreat extend longer
month lost load dose pool data wamd patient show chang
chang baselin bcva addit visual acuiti improv retin anatomi oct cst
wamd patient current treatment maintain period
remain requir everi month monthli treatment
dme potenti reduc load dose treatment interv shown
dme treat eye extend month longer load dose without
receiv retreat gone longer month last load dose
extend month longer dme patient chang baselin bcva week
dme current anti-vegf agent dose monthly/everi month monthli load
page
differenti phase durabl look encourag across wamd dme rvo
rvo current agent label monthli dose goal reduc number
load dose extend treatment interv month beyond phase studi patient
dose extend month longer last load dose patient
extend month longer chang baselin week mean bcva show
dr current agent label monthly/everi month dose monthli load dose
npdr shown earli sign improv dr concomit dme patient
improv dr sever level within first treatment
page
differenti durabl look encourag base phase data
wamd treat gone longer month last load dose compar
everi month eylea everi month beovu
dme gone longer month last load dose compar everi month eylea
rvo treat gone longer month last load dose compar everi
month eylea/lucenti
page
differenti efficaci data baselin mean bcva oct encourag
page
phase data wamd seem track well compar eylea
note phase studi open label bcva oct gener stabl
interv consist prolong durat effect bcva oct tend fluctuat
small amount month-to-month basi clinic trial
shown chang baselin week bcva week compar
eylea mean chang bcva rang week
page
schedul mg monthli initi dose subsequ dose per protocol-specifi retreat criteriadevelop phasephas ongoinglatest data latest data phase patient maintain visual acuiti letter bcva patient maintain visual acuiti letter bcva chang bcva measur etdr letter score chang bcva measur etdr letter score ls mean ls mean patient gain least letter vision baselin patient gain least letter vision baselin chang baselin week mean bcva oct bcva etdr letter end week oct cst micron end week chang baselin week mean bcva oct bcva etdr letter end week oct cst micron end week micronsview studi studi week week week week mg ml intravitr inject everi week approxim everi day monthli first month follow mg ml via intravitr inject everi week month approv
phase data dme seem track well compar eylea
shown chang form baselin week bcva compar eylea
mean chang bcva rang week
page
mg monthli initi dose subsequ dose per protocol-specifi retreat criteriadevelop phasephas plannedlatest data phase outcom week mg mg mg mg chang bcva measur etdr letter score baselin ls mean patient gain least letter bcva baselin differencec outcom week mg mg mg mg chang bcva measur etdr letter score baselin ls mean patient gain least letter bcva baselin differencec chang baselin week mean bcva oct bcva etdr letter end week oct cst micron end week chang baselin week mean bcva oct bcva etdr letter end week oct cst micron end week micronsefficaci resultsapprov markettedphas mg ml administ intravitr inject everi week approxim everi day monthli first inject follow mg ml via intravitr inject everi week month
differenti efficaci data rvo baselin mean bcva oct encourag
rvo character higher level intraocular vegf averag compar wet dme
current approv treatment label monthli dose
recent uk studi patient central rvo demonstr less-than-monthli dose
associ poorer outcom oct va
phase data shown patient extend month longer
last load dose
goal reduc load dose extend treatment interv month
favor compar monthli dose eylea/lucenti rvo
page
phase data rvo seem track well compar eylea
shown chang form baselin week bcva compar eylea
mean chang bcva rang week
page
mg monthli initi dose subsequ dose per protocol-specifi retreat criteriadevelop phasephas plannedlatest data phase mg week mg week mg week patient gain least letter bcva baselin patient gain least letter bcva baselin differ differencea chang bcva measur etdr letter score baselin chang bcva measur etdr letter score baselin sd ls mean ls chang baselin week mean bcva oct bcva etdr letter end week oct cst micron end week chang baselin week mean bcva oct bcva etdr letter end week oct cst micron end week micronsefficaci outcom week full analysi set locf copernicu galileoefficaci outcom week full analysi set locf vibrantapproved/marketedphas mg ml intravitr inject everi week kodiak scienc inc
rvo overview
rvo diseas character higher level intraocular vegf averag compar wamd
dme could lead vision loss
page
differenti could address limit real-world/few inject
treat extend common approach treat retin diseas patient howev
approach often lead sub-optimal dose eventu vision drop baselin bcva
accord kod parti market research real world practic retin specialist inject
anti-vegf less frequent indic label physician treat wamd patient follow
label dose interv prefer use treat extend dose instead result
new wamd patient receiv monthli load dose due patient barrier travel burden
oop cost physician percept
page
address limit seen current treatment retin diseas
inject burden inconveni patient
combin treat-and-extend dose result lower
complianc poorer visual outcom
eylea lucenti effect dose
adher accord label interv adher
accord label need durabl
current agent requir frequent anti-vegf inject
mean durabl wk mainten phase
also need decreas inject burden
modal also explor offer infrequ
inject extend durabl implant
microparticl gene therapi
along durabl need better long-term
page
rs treat wamd sub-optimal dose lead poorer outcom real world
accord kod parti market research retin specialist dont follow label dose
interv treat wamd patient treat-and-extend basi patient conveni portion
patient discontinu treatment due burnout scar
page
world use anti-vegf wamd
accord kod parti market research retin specialist treat wamd treat-and-extend basi
per label new wamd receiv monthli load dose due sever barrier physician
percept valu averag dose schedul rather label dose regimen
patient travel burden oop out-of-pocket cost
physician percept perceiv valu adher monthli load inject
treat-and-extend phase start earlier delay load inject
page
treat extend dose common non-inferior monthli rx treatment still preval
major unmet need durabl anti-vegf provid decreas treatment burden
better long-term visual outcom
treat wamd individu anti-vegf therapi use across avail agent lucenti eylea
avastin off-label physician believ similar efficaci safeti durabl
treatment requir indefinit frequent treatment evalu
howev real world rel treatment preval result sub-optimal outcom
beyond year studi earli detect help better vision less treatment
individu anti-vegf therapi use treat wamd avoid treatment safer cost effect
physician treat either use prn nata need treat extend basi
goal suppress cnv growth secondari exud oct imag use assess diseas control
page
rvo present opportun fewer inject
phase shown provid fast durabl respons rvo last effect
month without retreat load dose compar monthli dose eylea/lucenti
rvo propos phase design reduc load dose fix first month
page
rvo could improv outcom fewer load phase inject
rvo patient show sub-optimal respons anti-vegf treatment requir
aflibercept ranibizumab bevacizumab show signific vision improv rvo patient
respons anti-vegf
howev frequent inject need maintain vision oct improv
high unmet need anti-vegf offer durabl mani patient receiv
monthli inject load phase retin specialist use treat-and-extend
approach real world often result sub-optimal result discontinu current
anti-vegf treatment often due lack success/limit benefit sub-optimal respons lack
page
prior studi highlight treatment burden frequent load dose rvo
page
pivot non-inferior studi wamd dme rvo eylea
page
differenti favor safeti profil in-lin inflamm date
shown multiple-dos exposur well-toler intraocular inflamm date
similar eylea/lucenti
newer treatment approv develop shown higher rate inflamm
beovu shown greater durabl effect dose compar eylea
intraocular inflamm could concern beovu show slightli higher rate inflamm
beovu vs eylea note patient posit ada anti-drug antibodi beovu
like due molecular structur beovu novarti nv nr note effect
antibodi efficaci safeti unclear
allergan buy gilbert abicipar pegol sequoia cedar studi achiev non-
inferior ranibizumab dose howev note intraocular
inflamm event abicipar vs lucenti sequoia
abicipar vs lucenti cedar
page
concern competit approv product develop
brand anti-vegf market signific market opportun global sale
kod parti market research data note market expect grow annual driven
penetr dme also note diabet retinopathi result diabet
global preval grow expect grow base idf
eylea/lucenti standard care regimen requir frequent dose interv beovu
recent approv anti-vegf demonstr greater reduct retin fluid central retin
thick compar eylea efficaci interv howev slightli higher
rate inflamm beovu vs eylea may concern
see room multipl player believ offer first-in-class treatment
robust safety/efficaci data differenti durabl profil
page
concern competit recent approv beovu wamd
hawk harrier non-inferior studi beovu show efficaci durabl
compar eylea dose wet achiev flexibl dose load
page
ci beovu ci beovu eyleamean chang bcva wk wk wk wk wk wk wk wk wk wk wk wk wk wk wk wk wk wk wk wk wk wk wk wk drug reaction vision blurredcataractconjunctiv hemmorrhagevitr floatersey painintraocular inflammationintraocular pressur increasedretin hemorrhagevitr detachmentconjunctivitisretin pigment epitheli tearcorn abrasionhypersensitivitypunct keratitisretin tearbeovu control drug reaction retin tearendophthalmitisblindnessretin arteri occlusionretin detchamentconjunctiv hyperemialacrim increasedabnorm sensat eyedetach retin pigment epitheliumbeovu control se chang baselin bcva measur etdr letter score proport patient gain visual acuiti letter bcva proport patient lost visual acuiti letter bcva
concern competit recent approv beovu wamd
beovu label dose believ could allow flexibl dose far
await data pivot phase dazzl wamd studi
similar beovu pivot studi evalu compar eylea
per label dose recommend
howev highlight even eylea label could dose one year
effect therapi wherea beovu use right load phase
page
concern competit biosimilar develop
biosimilar eylea lucenti may price discount compar note
biosimilar compet within eylea lucenti market price per dose
speak kol note shown differenti durabl profil
physician find conveni patient burn current ivt treatment
thu see biosimilar compet within eylea lucenti market share ksi-
could benefit penetr new patient
page
biosimilar competitionrefer drugdevelop relat relat relat agwet relat biopeiswet relat conditionssourc compani report
concern sustain durabl efficaci outcom pivot studi
world data indic patient receiv fewer inject lead sub-optimal
dose poorer outcom thu need treatment better durabl outcom
emerg durabl data phase shown potenti longer dose interv
await phase data updat
page
concern could payer pushback issu
investor concern brand anti-vegf treatment could offer higher
rebat keep market share vocal increas price
price concern medicar advantag plan implement step therapi manag part
step therapi requir patient go lower price drug go brand eylea
speak kol learn physician may find uneth withhold effect
treatment patient efficaci durabl compar current treatment
accord drcr net protocol guidelin eylea lucenti price per dose
consid first line therapi may prescrib avastin off-label price per
base kod parti market research retin specialist primarili treat patient retin
diseas want therapi improv efficaci safeti better dose interv allow
improv conveni could give better outcom durabl
real world practic retin specialist typic follow label dose interv note
kod parti market research data howev recent studi leavo may suggest
failur follow label load dose schedul lead poorer outcom
thu drug like dose fewer load dose longer
believ physician want offer patient conveni dose better outcom
could prefer option reduc sub-optimal dose
page
page
incom product oper itemsnet interest incom incom provis net redeem convert prefer dividend relat benefici dividend convers redeem convert prefer net incom avail common ep ep chang non- provis tax net ep ep share share kodiak scienc inc
page
number million except share asset expens current current cash non-curr non-curr liabilitiesaccount expens current current convert prefer stock warrant equitypref paid-in liabil
page
number million except share flow oper net incom reconcil non-cash litig compens amort fair valu convert prefer stock asset expens current current flow invest purchas properti properti flow financingproce issuanc common stock net underwrit commiss issuanc common stock upon option issuanc redeem convert prefer repurchas earli exercis stock issuanc payment capit payment tenant improv allow
chairman chief execut offic victor perloth
co-found kodiak scienc dr perlroth serv ventur partner entrepreneur resid
mpm capit dr perlroth co-found avidia inc serv gener manag vice presid corpor
develop dr perlroth one key member involv acquisit compani prior dr
perlroth work guzik technic enterpris serv chief oper offic dr perlroth receiv
 degre stanford univers molecular biolog summa cum laud princeton
john borgeson senior vice presid cfo sinc join kodiak mr borgeson led financ function
numer privat biotech compani includ labri biolog inc acquir
prior mr borgeson vice presid financ pfizer inc head financ
biotherapeut bioinnov group corpor tax execut europ mr borgeson
led restructur global tax group serv model fortun compani mr borgeson began
career auditor ernst young mr borgeson receiv undergradu degre
school manag univers buffalo
page
chief medic offic chief develop offic jason ehrlich ph
dr ehrlich serv chief develop offic prior join kodiak dr ehrlich serv global
head clinic ophthalmolog genentech lead clinician lucenti diabet eye diseas
first fda approv intraocular drug dme later expand label form diabet
retinopathi dr ehrlich well-known leadership expertis ophthalm drug develop particip
overseen numer sbla fda european health author interact dr ehrlich also led integr
ophthalm drug deliveri compani forsight genentech/roch includ oversight success
phase ii studi ranibizumab port deliveri system led design execut pivot phase program
lampalizumab patient across countri also led transit global phase develop
faricimab novel bispecif antibodi retin vascular diseas dr ehrlich receiv ph degre
stanford receiv molecular biolog summa cum laud princeton univers
hong liang vice presid discoveri medicin sinc decemb dr liang lead kodiak discoveri effort
goal design import medicin prevent and/or slow retin diseas progress high risk patient prior
kodiak dr liang senior director rinat laboratori pfizer inc led genom comput
biolog group focus target discoveri translat biomark work previous respons mani
preclin project metabol neurolog diseas rinat/pf includ project initi inventor
program dr liang led express profil knockout construct gener effort deltagen inc dr liang train
postdoctor fellow stanford univers earn ph degre northwestern univers complet requir
biolog univers scienc technolog china
page
overal compens plan appear line sharehold interest name execut offic elig
earn incent bonu base individu perform goal well corpor goal relat product
develop advanc clinic studi compens execut structur around
achiev corpor goal mileston year base subject object perform
goal determin board director
page
kodiak scienc inc clinical-stag biopharmaceut compani engag
develop novel therapi treatment retin diseas product pipelin includ
wet dme dr rvo dme uveiti compani found
stephen charl victor perlroth headquart palo alto ca
rate share buy
believ antibodi biopolym conjug platform fulli appreci platform
allow longer durabl intravitr treatment ivt would allow improv complianc
efficaci fewer visit platform valid lead drug candid anti-
vegf antibodi similar antibodi compon eylea lucenti bispecif anti-
uveiti
like risk reward pivot phase dazzl non-inferior studi vs eylea wet
base phase data wet week show mean chang
bcva compar harrier studi show week time point boevu
showedd eylea harrier studi dazzl data non-inferior eylea
show durabl longer eylea dose see confid read-through phase
data rvo dme dr read could result dcf
data updat weekend angiogenesi confer miami could give investor
confid dazzl data kodiak pursu approv across indic bla
rvo primari endpoint data sbla file wet pivot
phase data endpoint data dme dr
simpl stori two way look valuat view conserv
approach could backdrop price pressur anti-vegf market could
price premium current agent rebat potenti biosimilar use patient
adequ treat eylea lucenti use later line therapi
could captur market share brand anti-vegf sale aggress
scenario assum perceiv highli differenti longer interv dose
favor visual acuiti improv physician place ahead eylea scenario
could take share perceiv better patient offer real world
coverag durabl case could see even upsid
compani well-capit cash balanc includ recent equiti financ
royalti agreement cap futur royalti exchang close
jan fund baker bro advisor bba provid cash runway beyond
valuat risk
pt deriv probabl adjust dcf discount rate appropri risk
associ smid-cap biotech appli probabl account phase
success risk includ regulatori risk obtain approv clinic risk
provid sustain respons inferior eylea commerci risk penetr intravitr
compani mention note
robyn karnauska herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
page
